424 related articles for article (PubMed ID: 34798882)
1. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
2. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
3. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
4. MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer.
Xu H; Mao HL; Zhao XR; Li Y; Liu PS
J Ovarian Res; 2020 Mar; 13(1):31. PubMed ID: 32192508
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
6. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
7. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
8. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
9. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.
Liu M; Peng J
Comput Math Methods Med; 2022; 2022():2318170. PubMed ID: 35651928
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
11. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
12. CircAGFG1 Promotes Ovarian Cancer Progression Through the miR-409-3 p/ZEB1 Axis.
Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
[TBL] [Abstract][Full Text] [Related]
13. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
Zheng J; Zhou Y; Li XJ; Hu JM
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
Guo J; Pan H
Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K.
Geng L; Wang Z; Tian Y
J Ovarian Res; 2022 Jan; 15(1):1. PubMed ID: 34980214
[TBL] [Abstract][Full Text] [Related]
17. MiR-513a-3p inhibits EMT mediated by HOXB7 and promotes sensitivity to cisplatin in ovarian cancer cells.
Chen Y; Zhao XH; Zhang DD; Zhao Y
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10391-10402. PubMed ID: 33155195
[TBL] [Abstract][Full Text] [Related]
18. CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis.
Zhou J; Dong ZN; Qiu BQ; Hu M; Liang XQ; Dai X; Hong D; Sun YF
Aging (Albany NY); 2020 Jul; 12(14):14080-14091. PubMed ID: 32668414
[TBL] [Abstract][Full Text] [Related]
19. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
[TBL] [Abstract][Full Text] [Related]
20. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.
Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y
J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
